TAMs from SphK2-deficient tumors displayed a pronounced anti-tumor phenotype, showing an increased expression of the pro-inflammatory markers/mediators such as NO, TNF-α, IL-12 and MHCII and a low expression of anti-inflammatory IL-10 and CD206. Here, MRC1 is linked to neoplasm.